EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma

Future Oncology

Volumn 5, Issue 3, 2009, Pages 323-338

  Hudson, Laurie G ^a   Moss, Natalie M ^b   Stack, M Sharon ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c University of Missouri   (United States)

Author keywords

EGF receptor; Invasion; Metastasis; MMP 9; MTI MMP MMP 14; Ovarian carcinoma

Indexed keywords

BATIMASTAT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST; ERLOTINIB; GEFITINIB; LAPATINIB; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PANITUMUMAB; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ASCITES; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; INFLAMMATORY CELL; LUNG NON SMALL CELL CANCER; METASTASIS; MICROENVIRONMENT; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 66949178329     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.10     Document Type: Review

References (159)

1. Shedden KA, Kshisager MP, Schwartz DR et al.: Histologic type, organ or origin and wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin. Can. Res. 11, 2123-2131 (2005).
2. Shih IM, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Path. 164, 1511-1518 (2004).
3. Schwartz DR, Kardia SLR, Shedden KA et al.: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Can. Res. 62, 4722,4729 (2002).
4. Scully RE, Young RH, Clement PB: Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Atlas of Tumor Pathology (Third Series, Fascicle 23). Armed Forces Institute of Pathology, Washington, DC, USA (1998).
5. Lafky JM, Wilken JA, Baron AT, Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785(2), 232-265 (2008).
6. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005).
7. Mendelsohn J, Baselga J: Epidermal growth, factor receptor targeting in cancer. Semin. Oncol. 33(4), 369-385 (2006).
8. Normanno N, De Luca A, Bianco C et al.: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2-16 (2006).
9. Burleson KM, Hansen LK, Skubitz APN: Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 21, 685-697 (2004).
10. Burleson KM, Casey RC, Skubitz KM et al.: Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93, 170-181 (2004).
11. Burleson KM, Boente MP, Pambuccian SE et al.: Disaggreation and invasion of ovarian carcinoma ascites spheroids. J. Translational Med. 4, 1-16 (2006).
12. Seidman JD, Russell P, Kurman RJ: Surface epithelial tumors of the ovary. In: Blaustein's Pathology of the Female Genital Tract. Kurman RJ (Ed.). Springer Press, Germany 791-820 (2002).
13. Hudson LG, Zeineldin R, Silberberg M, Stack MS: Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res. (2009) (In press).
14. Kenny HA, Krausz T, Yamada SD et al.: Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer 121, 1463-1472 (2007).
15. Barbolina MV, Moss NM, Westfall SD et al.: Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat. Res. (2009) (In press).
16. Offner FA, Obrist P, Stadlmann S et al.: IL6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7, 542-547(1995).
17. Mustea A, Pirvulescu C, Konsgen D et al.: Decreased IL1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 42, 77-84 (2008).
18. Freedman RS, Deavers M, Liu J et al.: Peritoneal inflammation - a microenvironment for epithelial ovarian cancer. J. Trans. Med. 2, 23-33 (2004).
19. Gortzak-Uzan L, Ignarchenko A, Evangelou AI et al.: A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatics analyses to identify putative biomarkers. J. Proteome Res. 7, 339-351 (2008).
20. Singh AP, Senapati S, Ponnusamy MP et al.: Clinical potential of mucins in diagnosis, prognosis and therapy of ovarian cancer. Lancet Oncol. 9, 1076-1085 (2008).
21. Bazley LA, Gullick WJ: The epidermal growth factor receptor family. Endocr. Relat. Cancer 12(Suppl. 1), S17-S27 (2005).
22. Linggi B, Carpenter G: ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16(12), 649-656 (2006).
23. Citri A, Yarden Y: EGF-ERBB signaling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7(7), 505-516 (2006).
24. Wieduwilt MJ, Moasser MM: The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65(10), 1566-1584 (2008).
25. Harari PM, Allen GW, Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 25 (26), 4057-4065 (2007).
26. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160-1174 (2008).
27. Amit I, Wides R, Yarden Y: Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 3, 151 (2007).
28. Zandi R, Larsen AB, Andersen P et al.: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19(10), 2013-2023 (2007).
29. Riese D, Gallo R, Settleman J: Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays 29(6), 558-565 (2007).
30. Lassus H, Sihto H, Leminen A et al.: Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. 84(8), 671-681 (2006).
31. Psyrri A, Kassar M, Yu Z et al.: Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin. Cancer Res. 11 (24 Pt 1), 8637-8643 (2005).
32. Crijns APG, Boezen HM, Schouten JP et al.: Prognostic factors in ovarian cancer: current evidence and future prospects. The ECCO 12 Educational Book. Eur. J. Cancer 1(Suppl.), 127-145 (2003).
33. Tsakiridis T, Cutz JC, Singh G et al.: Association of Phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J. Thorac. Oncol. 3(7), 716-722 (2008).
34. Sonnweber B, Dlaska M, Skvortsov S et al.: High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J. Clin. Pathol. 59(3), 255-259 (2006).
35. Kanematsu T, Yano, S, Uehara H et al.: Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol. Res. 13(5), 289-298 (2003).
36. Papouchado B, Erickson LA, Rohlinger AL et al.: Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol. 18(10), 1329-1335 (2005).
37. Kong A, Leboucher P, Leek R et al.: Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res. 66(5), 2834-2843 (2006).
38. Gun L, Abraham J, Flynn DC, Castranova V, Shi X, Qian Y: Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins. Int. J. Biol. Markers. 22(1), 1-11 (2007).
39. De Graef P, Crijns AP, Ten Hoor KA et al.: The ErbB signaling pathway protein expression and prognostic value in epithelial ovarian cancer. Br. J. Cancer 99, 341-349 (2008).
40. Posadas EM, Liel MS, Kwitkowski V et al.: A Phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7), 1323-1330 (2007).
41. Cowden Dahl KD, Symowicz J, Ning Y et al.: Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 68, 46-06-4613 (2008).
42. Miyamoto S, Yagi H, Yotsumoto F et al.: New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res. 27(6A), 3713-3721 (2007).
43. Miyamoto S, Yagi H, Yotsumoto F et al.: Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy. Adv. Exp. Med. Biol. 622, 281-295 (2008).
44. Braun AH, Coffey RJ: Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last. Clin. Cancer Res 11(13), 4639-4643 (2005).
45. Tanaka Y, Miyamoto S, Suzuki SO et al.: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin. Cancer Res. 11 (13), 4783-4792 (2005).
46. Miyamoto S, Hirata M, Yamazaki A et al.: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 64(16), 5720-5727 (2004).
47. Prenzel N, Zwick E, Daub H et al.: EGF receptor transactivation by G-protein-coupled receptors requires etalloproteinase cleavage of proHB-EGF. Nature 402(6764), 884-888 (1999).
48. Hsieh M, Conti M: G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol. Metab. 16(7), 320-326 (2005).
49. Fischer OM, Hart S, Ullrich A: Dissecting the epidermal growth factor receptor signal transactivation pathway. Methods Mol. Biol. 327, 85-97 (2006).
50. Bhola NE, Grandis JR: Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 13, 1857-1865 (2008).
51. Deryugina El, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25 (1), 9-34 (2006).
52. Itoh Y, Nagase H. Matrix metalloproteinases in cancer. Essays Biochem. 38, 21-36 (2002).
53. Ghosh S, Wu Y Stack MS: Ovarian cancer-associated proteinases. Cancer Treat. Res. 107, 331-354 (2002).
54. Kamat AA, Fletcher M, Gruman LM et al.: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin. Cancer Res. 12(6), 1707-1714 (2006).
55. Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS: Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80 (8), 1457-1463 (1997).
56. Symowicz J, Adley BP, Gleason KJ et al.: Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 67, 2030-2039 (2007).
57. Demeter A, Sziller I, Csapo Z et al.: Molecular prognostic markets in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res. 25(4), 2885-2889 (2005).
58. Lengyel E, Schmalfeldt B, Konik E et al.: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 82(2), 291-298 (2001).
59. Yan C, Boyd DD: Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 211(1), 19-26 (2007).
60. Mancini A, Di Battista JA: Transcriptional regulation of matrix metalloprotease gene expression in health and disease. Front. Biosci. 11, 423-446 (2006).
61. Vincenti MP, Brinckerhoff CE: Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J. Cell. Physiol. 213(2), 355-364 (2007).
62. Ellerbroek SM, Halbleib JM, Benavidez M et al.: Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61(5), 1855-1861 (2001).
63. Ellerbroek SM, Hudson LG, Stack MS: Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int. J. Can. 78(3), 331-337 (1998).
64. Zhou HY, Pon YL, Wong AS: Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology 148(11), 5195-5208 (2007).
65. Cowden Dahl KD, Zeineldin R, Hudson LG: PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol. Cancer Res. 5, 413-421 (2007).
66. Kheradmand F, Rishi K, Werb Z: Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J. Cell. Sci. 115, 839-848 (2002).
67. Van Meter TE, Broaddus WC, Rooprai HK, Pilkington GJ, Fillmore HL: Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. J. Neurooncol. 6, 188-199 (2004).
68. Chotteau-Lelievre A, Desbiens X, Pelczar H, Defossez PA, de Launoit Y: Differential expression patterns of the PEA3 group transcription factors through routine embryonic development. Oncogene 15, 937-952 (1997).
69. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R: PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin. Cancer Res. 9, 1412-1419 (2003).
70. Hibbs K, Skubitz KM, Pambuccian SE et al.: Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165, 397-414 (2004).
71. Koo TB, Song H, Moon I et al.: Differential expression of the PEA3 subfamily of ETS transcription factors in the mouse ovary and peri-implantation uterus. Reproduction 129, 651-657 (2005).
72. Lynch CC, Crawford HC, Matrisian LM, McDonnell S: Epidermal growth factor upregulates matrix metalloproteinase-7 expression through activation of PEA3 transcription factors. Int. J. Oncol. 24, 1565-1572 (2004).
73. de Launoit Y, Baert JL, Chotteau-Lelievre A et al.: The Ets transcription factors of the PEA3 group: Transcriptional regulators in metastasis. Biochim. Biophys. Acta 1766, 79-87 (2006).
74. Gum R, Lengyel E, Juarez J et al.: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271, 10672-10680 (1996).
75. Habelhah H, Okada F, Kobayashi M et al.: Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression. Oncogene 18, 1771-1776 (1999).
76. Pendas AM, Balbin M, Llano E, Jimenez MG, Lopez-Otin C: Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Genomics 40, 222-233 (1997).
77. Tardif G, Reboul P, Dupuis M et al.: Transforming growth factor-α induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and PEA-3 binding sites. J. Rheumatol. 28, 1631-1639 (2001).
78. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R: High affinity binding of latent matrix metalloproteinase-9 to the a2(IV) chain of collagen IV. J. Biol. Chem. 273, 10672-10681 (1998).
79. Bourguignon LY, Gunja-Smith Z, Iida N et al.: CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176, 206-215, (1998).
80. Yu Q, Stamenkovic I: Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD440-mediated tumor invasion. Genes Dev. 13, 35-48 (1999).
81. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14(2), 163-176 (2000).
82. Toth M, Gervasi CD, Fridman R: Phorbol ester induced cell surface association of matrix metalloproteinase 9 in human MCF10A breast epithelial cells. Cancer Res. 57, 3159-3167 (1997).
83. Koyama Y, Naruo H, Yoshitomi Y et al.: Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells. J. Biocbem. 143(5), 581-592 (2008).
84. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS: CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int. J. Oncol. 31(5), 1119-1126 (2007).
85. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S: Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 22(2-3), 153-166 (2003).
86. Ouyaug M, Lu S, Li XY et al.: Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging. J. Biol. Chem. 283, 17740-17748 (2008).
87. Ning Y, Buranda T, Hudson LG: Activated epidermal growth factor receptor induces integrin α2 internalization via caveolae/raft-dependent endocytic pathway. J. Biol. Chem. 282(9), 6380-6387 (2007).
88. Moss, NM, Liu Y, Johnson JJ et al.: Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol. Can. Res. (2009) (In press).
89. Wilhelm O, Hafter R, Coppenrath E et al.: Fibrin-fibronectin compunds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res. 48, 3507-3514 (1988).
90. Hafter R, Klaubert W, Gollwitzer R, von Hugo G, Graeff H: Crosslinked fibrin derivatives and fibronectin in ascetic fluid from patients with ovarian cancer compared with ascetic fluid in liver cirrhosis. Thromb. Res. 35, 53-64 (1984).
91. Crickard K, Niedbala MJ, Crickard U et al.: Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol. Oncol. 32, 163-173 (1989).
92. Cracchiolo BM, Hanauske-Abel HM, Schwartz PE, Chambers JT, Holland B, Chambers SK: Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Gynecol. Oncol. 87, 24-33 (2002).
93. Santala M, Risteli J, Risteli L et al.: Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br. J. Cancer 77, 1825-1831 (1998).
94. Zhu GG, Risteli J, Puistola U et al.: Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res. 53, 5028-5032 (1993).
95. Abdel Aziz MT, Abdel Aziz Wassef M, Kamel M et al.: Clinical evaluation of serum aminoterminal propeptide of type III procollagen as tumor marker in gynecologic malignancies. Tumori. 79, 219-223 (1993).
96. Sood AK, Seftor EA, Fletcher MS et al.: Mole-cular determinants of ovarian cancer plasticity. Am. J. Pathol. 158(4), 1279-1288 (2001).
97. Sood AK, Fletcher MS, Coffin JE et al.: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am. J. Obstet. Gynecol. 190(4), 899-909 (2004).
98. Kenny HA, Kaur S, Coussen LM, Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 118, 1367-1379 (2008).
99. Adley BP, Gleason KJ, Yang XJ, Stack MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol. Oncol. 112(2), 319-324 (2009).
100. Moss NM, Barbolina MV, Liu Y et al.: Ovarian carcinoma cell detachment and multi-cellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in intra-peritoneal metastatic dissemination. Cancer Res. (2009) (In press).
101. Ellerbroek SM, Wu YI, Overall CM et al.: Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem. 276, 24833-24842 (2001).
102. Ellerbrock SM, Fishman DA, Kearns AS et al.: Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through β1 integrin. Cancer Res. 59, 1635-1641 (1999).
103. Kenny HA, Dogan S, Zillhardt M et al.: Organotypic models of metastasis: a 3 dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat. Res. (2009) (In press).
104. Barbolina MV, Adley BP, Ariztia EV et al.: Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 282, 4924-4931 (2007).
105. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS: Characterization of gelatinases linked to matrix invasion in ovarian adenocarcinoma. Gynecol. Oncol. 62(1), 89-99 (1996).
106. Moser TL, Pizzo SV, Bafetti LM et al.: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin. Int. J. Cancer 67, 695-701 (1996).
107. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M: Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression inepithelial ovarian tumors. Eur. J. Gynaecol. Oncol. 24(5), 417-420 (2003).
108. Naylor MS, Stamp GW, Davies BD, Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int. J. Cancer 58; 50-56 (1994).
109. Huang S, Van Arsdail M, Tedjarati S et al.: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl Cancer Inst. 94(15), 1134-1142 (2002).
110. Davidson B, Goldberg I, Gotlieb WH et al.: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 17, 799-808 (1999).
111. Davidson B, Goldberg I, Gotlieb WH et al.: The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol. Cell. Endocrinol. 187, 39-45 (2002).
112. Cai KQ, Yang WL, Capo-Chichi CD et al.: Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol. Carcinogen 46, 130-143 (2007).
113. Belotti D, Paganoni P, Manenti L et al.: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63, 5224-5229 (2003).
114. Belotti D, Calcagno C, Garofalo A et al.: Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol. Can. Res. 6, 525-534 (2008).
115. Herrera CA, Xu L, Bucana CD et al.: Expression of metastasis-related genes in humanepithelial ovarian tumors. Int. J. Oncol. 20, 5-13 (2002).
116. Holmbeck K, Bianco P, Caterina J et al.: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99(1), 81-92 (1999).
117. Zhou Z, Apte SS, Soininen R et al.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97(8), 4052-4057 (2000).
118. Sabeh F, Ota I, Holmbeck K et al.: Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167(4), 769-781 (2004).
119. Seiki M, Yana I: Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 94(7), 569-574 (2003).
120. Zhai Y, Hotary KB, Nan B et al.: Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res. 65, 6543-6550 (2005).
121. Itoh Y, Seiki M: MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell Physiol. 206(1), 1-8 (2006).
122. Afzal S, Lalani EN, Poulsom R et al.: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum. Pathol. 29(2), 155-165 (1998).
123. Drew AF, Blick TJ, Lafleur MA et al.: Correlation of tumor-and stromal-derived MT1-MMP expression with progression of human ovarian rumors in SCID mice. Gynecol. Oncol. 95, 437-448 (2004).
124. Fishman DA, Kearns AM, Chilikuri K et al.: metastatic dissemination of human ovarian epithelial carcinoma is promoted by α2β1 integrin-mediated interaction with type I collagen. Invasion Metastasis 18, 15-26 (1998).
125. Wu X, Li H, Kang L, Li L, Wang W, Shan B: Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol. 84, 126-134 (2002).
126. Kajita M, Itoh Y, Chiba T et al.: Membrane- type I matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Bio. 153, 893-904 (2001).
127. Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Béliveau R: Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane- type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 507(2), 231-236 (2001).
128. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ: Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell. Biol. 149(6), 1309-1323 (2000).
129. Hotary KB, Allen ED, Brooks PC et al.: Membrane type 1 matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114, 33-45 (2003).
130. Harvey W, Amlot P: Colalgen production by human mesothelial cells in vitro. J. Pathol. 139, 337-347 (1983).
131. Stylianou E, Jenner LA, Davies M et al.: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 37, 1563-1570 (1990).
132. Sodek KL, Ringuette MJ, Brown TJ: MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br. J. Cancer 97, 358-367 (2007),
133. Niedbala MJ, Crickard K, Bernacki RJ: Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. An in vitro model system for studying tumor cell adhesion and invasion. Exp. Cell Res. 160(2), 499-513 (1985).
134. Niedbala MJ, Crickard K, Bernacki RJ: In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin. Exp. Mets. 5, 181-197 (1987).
135. Sawada K, Mitra AK, Radjabi AR et al. Loss of E-cadherin promotes ovarian cancer metastasis via α5 integrin, which is a therapeutic target. Cancer Res. 68, 2329-2339 (2008).
136. Cannistra SA, Kansas GS, Niloff J et al.: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Can. Res. 53, 3830-3838 (1993).
137. Casey RC, Burleson KM, Skubitz KM et al.: β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am. J. Pathol. 159 (6), 2071-2080 (2001).
138. Frankel A, Rosen K, Filmus J, Kerbel RS: Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res. 61(12), 4837-4841 (2001).
139. Kassis J, Lkominek J, Kohn EC: Tumor microenvironment: what can effusions teach us? Diagnostic Cytopathology 33, 316-319 (2004).
140. Steeg PS, Theodorescu D/1 Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 5(4), 206-219 (2008).
141. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N: Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 99(2), 214-220 (2008).
142. Martin MD, Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 26(3-4), 717-724 (2007).
143. Fingleton B: MMPs as therapeutic targets - still a viable option? Semin. Cell Dev. Biol. 19(1), 61-68 (2008).
144. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53, 2087-2091 (1993).
145. Nemunaitis J, Poole C, Primrose J et al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4, 1101-1109 (1998).
146. Malfetano J, Teng N, Barter J: Marimastat in patients with advanced cancer of the ovary: a dose-finding study. Proc. Am. Soc. Clin. Oncol. 16, 373a (1997).
147. Poole C, Adams M, Barley V: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor in patients with advanced ovarian cancer. Ann. Oncol. 7, 68 (1996).
148. Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer (3), 227-239 (2006).
149. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann. Oncol. 18(Suppl. 6), vi35-vi41 (2007).
150. Palayekar MJ, Herzog TJ: The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int. J. Gynecol. Cancer. 18(5), 879-890 (2008).
151. Schilder RJ, Sill MW, Chen X et al.: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin. Cancer Res. 11(15), 5539-5548 (2005).
152. Dimova I, Zaharieva B, Raitcheva S, Dimitrov R, Doganov N, Toncheva D: Tissue microarray analysis of FGFR and erbB2 copy number changes in ovarian tumors. Int. J. Gynecol. Cancer. 16(1), 145-151 (2006).
153. Stadlmann S, Gueth U, Reiser U et al.: Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod. Pathol. 19(4), 607-610 (2006).
154. Baselga J, Rosen N: Determinants of RASistance to anti-epidermal growth factor receptor agents. J. Clin. Oncol. 26(10), 1582-1584 (2008).
155. Gelovani JG: Molecular imaging depidermal growth factor receptor expression-activity at the kinase level in tumors with position emission tomography. Cancer Metastasis Rev. 27(4), 645-653 (2008).
156. Yagi H, Yotsumoto F, Miyamoto S: Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol. Cancer Ther. 7(10), 3441-3451 (2008).
157. Rosanò L, Di Castro V, Spinella F et al.: Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res. 67(13), 6351-6359 (2007).
158. Tortora G, Ciardiello F, Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat. Clin. Pract. Oncol. 5(9), 521-530 (2008).
159. Markman M: The promise and perils of targeted therapy' of advanced ovarian cancer. Oncology 74(1-2), 1-6 (2008).